FDA approves Pfizer’s RSV vaccine for older adults
The Food and Drug Administration approved a second vaccine to protect older adults against RSV on Wednesday, giving a green light to Pfizer’s Abrysvo for adults 60 and older.
Early in May the FDA approved the first ever vaccine against respiratory syncytial virus, or RSV, when it licensed GSK’s Arexvy.
Read Original Article: FDA approves Pfizer’s RSV vaccine for older adults »
